Free Trial
NASDAQ:INAB

IN8bio (INAB) Stock Price, News & Analysis

IN8bio logo
$0.17 0.00 (-1.22%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$0.17 +0.00 (+0.82%)
As of 04/2/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IN8bio Stock (NASDAQ:INAB)

Key Stats

Today's Range
$0.16
$0.18
50-Day Range
$0.17
$0.32
52-Week Range
$0.16
$1.74
Volume
689,119 shs
Average Volume
1.85 million shs
Market Capitalization
$13.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Buy

Company Overview

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Remove Ads

IN8bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

INAB MarketRank™: 

IN8bio scored higher than 54% of companies evaluated by MarketBeat, and ranked 484th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IN8bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about IN8bio's stock forecast and price target.
  • Earnings Growth

    Earnings for IN8bio are expected to grow in the coming year, from ($0.56) to ($0.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IN8bio is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IN8bio is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    IN8bio has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about IN8bio's valuation and earnings.
  • Percentage of Shares Shorted

    2.58% of the float of IN8bio has been sold short.
  • Short Interest Ratio / Days to Cover

    IN8bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IN8bio has recently increased by 108.62%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IN8bio does not currently pay a dividend.

  • Dividend Growth

    IN8bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.58% of the float of IN8bio has been sold short.
  • Short Interest Ratio / Days to Cover

    IN8bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IN8bio has recently increased by 108.62%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    IN8bio has a news sentiment score of -0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for IN8bio this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IN8bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.50% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IN8bio's insider trading history.
Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

INAB Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Headlines

INAB Stock Analysis - Frequently Asked Questions

IN8bio's stock was trading at $0.2572 on January 1st, 2025. Since then, INAB shares have decreased by 33.7% and is now trading at $0.1706.
View the best growth stocks for 2025 here
.

IN8bio, Inc. (NASDAQ:INAB) issued its quarterly earnings data on Thursday, March, 13th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03.

IN8bio (INAB) raised $44 million in an IPO on Friday, July 30th 2021. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO.

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IN8bio investors own include NVIDIA (NVDA), Ford Motor (F), GitLab (GTLB), Cognition Therapeutics (CGTX), CrowdStrike (CRWD), Chevron (CVX) and Meta Platforms (META).

Company Calendar

Last Earnings
3/13/2025
Today
4/02/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INAB
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+3,427.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
0.29

Miscellaneous

Free Float
61,248,000
Market Cap
$13.82 million
Optionable
Not Optionable
Beta
0.03
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:INAB) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners